Key Highlights
- Oklo shares plummeted 9.1% during trading hours to approximately $45.68, with trading volume surpassing 10.6 million shares
- Fourth-quarter earnings per share came in at ($0.27), significantly worse than the ($0.17) analyst consensus
- Company executives and insiders offloaded more than 1.2 million shares valued at approximately $100.7 million during the previous quarter
- A pair of board members joined the selling spree on March 30, divesting a total of 14,500 shares
- Major Wall Street firms including UBS, Goldman Sachs, and B. Riley reduced their price forecasts, highlighting capital intensity and operational challenges
The nuclear energy startup has experienced a challenging period recently. Following a peak exceeding $190 within the past twelve months, shares have declined 30% since the start of the year and currently trade significantly beneath both the 50-day moving average of $68.12 and the 200-day moving average of $94.27.
The recent downturn resulted from a convergence of bearish developments — disappointing quarterly results, downward analyst revisions, and substantial insider stock disposals that caught investors’ attention.
Regarding financial performance, Oklo reported a quarterly loss of $0.27 per share, falling short of the ($0.17) Wall Street consensus by a full dime. While the magnitude may appear modest, for a pre-revenue enterprise where flawless execution is critical, the shortfall heightened investor anxiety.
Wall Street analysts contributed to the pessimistic mood. Major investment banks including UBS, Goldman Sachs, and B. Riley all lowered their price objectives, emphasizing substantial capital demands, accelerating cash consumption, and scheduling uncertainties surrounding Oklo‘s pioneering reactor construction projects. These apprehensions carry weight — the company remains pre-revenue, maintains aggressive spending patterns, and has not yet obtained final design certification from the Nuclear Regulatory Commission.
Nevertheless, bearish sentiment hasn’t been universal. Cantor Fitzgerald maintained its “overweight” recommendation with a $122 price objective as of March 18. The broader analyst community still rates the stock a “Moderate Buy” with a mean target of $84.30 — representing nearly a 100% premium to current levels. Texas Capital even elevated the stock to “Strong Buy” status in January.
Executive Stock Sales Intensify Concerns
The pattern of insider transactions has emerged as one of the most conspicuous warning signals in recent weeks. Throughout the last quarter, company insiders collectively divested 1,222,424 shares totaling roughly $100.7 million.
Chief Executive Jacob DeWitte disposed of 231,657 shares in January at $99.25 per share — reducing his ownership position by 21.88%. Chief Financial Officer Richard Craig Bealmear executed his own sale in March, offloading 72,090 shares at $60.00, trimming his stake by 15.74%.
On March 30, coinciding with the sharp stock decline, two board directors participated as well. Richard Kinzley sold 4,000 shares generating proceeds of $208,360, while John M. Jansen divested 10,500 shares for $540,960.
Insider selling of this magnitude, particularly from senior leadership positions, typically prompts investor scrutiny — regardless of whether executives characterize the transactions as pre-planned.
Positive Developments Remain
Despite mounting headwinds, Oklo maintains several legitimate growth drivers.
The enterprise holds over $2.6 billion in available liquidity, providing substantial operating runway. The Department of Energy has granted critical regulatory approvals, and the company’s Meta-supported Ohio development continues advancing on schedule. The firm also recently broadened its fast-reactor collaboration with Swedish partner Blykalla.
Its Atomic Alchemy division is advancing a radioisotope pilot facility with Department of Energy support, establishing an additional revenue stream for the future.
With a $7.93 billion market capitalization and zero current revenue, the valuation incorporates expectations of future success that carries substantial execution uncertainty. The technical indicators — bearish MACD momentum, trading beneath critical moving averages — mirror this fundamental tension.
The closing price during Monday’s trading session: $45.68, representing a 9.1% intraday decline.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
